New two-year data confirm Roche ’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration

In the TENAYA and LUCERNE studies, more than 60% ofVabysmo patientscould be treated every four months at two years. This represents an increase from 45% at year onePatients treated withVabysmo received a median number of 10 injections over the two years versus 15 injections for those treated withaflibercept, potentially decreasing the number of injectionsNo new safety signals were identified andVabysmo continued to be well tolerated, with afavourable benefit-risk profileBasel, 14 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo ® (faricimab) in neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of vision loss.1,2 Neovascular AMD affects nearly 20 million people globally and can require treatment with eye injections every one to two months.2,3,4 The two-year data were presented at the 2022 American Society of Retina Specialists Annual Scientific Meeting on 14 July.1“These longer-term results reinforce confidence in Vabysmo and support its continued use in people with neovascular AMD,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “With the potential to require fewer injections over time, Vabysmo continues to represent an important step forward for people with vision-threatening retinal conditions, and these data exemplify our commitment to redefining sta...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news